Filana Therapeutics Q2 FY26 net loss narrows 80.55% to $8.6 million

Reuters2026/07/29 12:04

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Filana Therapeutics posted a GAAP net loss of USD 8.6 million, or USD 0.18 per share, in Q2 2026, narrowing from USD 44.2 million.
R&D expense fell 35% to USD 3.3 million, due primarily to the phase-out of its Alzheimer’s disease program completed in Q2 2025.
G&A expense dropped 85% to USD 6.1 million, due primarily to a USD 31.25 million securities litigation loss contingency recorded in Q2 2025.
Cash and cash equivalents totaled USD 82.7 million at June 30, 2026; the company reported no debt.
Management said it is engaging with the FDA to address the clinical hold on its TSC-related epilepsy proof-of-concept trial; unrestricted year-end cash is guided at USD 36-40 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Filana Therapeutics Q2 FY26 net loss narrows 80.55% to $8.6 million

You may also like

Crypto prices